Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114853) titled 'A single-arm phase II clinical study to evaluate the efficacy and safety of neoadjuvant pembrolizumab combined with platinum and taxane-based doublet chemotherapy in the treatment of locally advanced HPV(-) head and neck squamous cell carcinoma' on Dec. 18, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-08-28
Target Sample Size: Experimental group:35;
Countries of Recruitment:
China
...